Cargando…
Risk of bias assessment of sequence generation: a study of 100 systematic reviews of trials
BACKGROUND: Systematic reviews of randomised trials guide policy and healthcare decisions. Yet, we observed that some reviews judge randomised trials as high or unclear risk of bias (ROB) for sequence generation, potentially introducing bias. However, to date, the extent of this issue has not been w...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323681/ https://www.ncbi.nlm.nih.gov/pubmed/30621793 http://dx.doi.org/10.1186/s13643-018-0924-1 |
_version_ | 1783385812624211968 |
---|---|
author | Wuytack, Francesca Regan, Maria Biesty, Linda Meskell, Pauline Lutomski, Jennifer E. O’Donnell, Martin Treweek, Shaun Devane, Declan |
author_facet | Wuytack, Francesca Regan, Maria Biesty, Linda Meskell, Pauline Lutomski, Jennifer E. O’Donnell, Martin Treweek, Shaun Devane, Declan |
author_sort | Wuytack, Francesca |
collection | PubMed |
description | BACKGROUND: Systematic reviews of randomised trials guide policy and healthcare decisions. Yet, we observed that some reviews judge randomised trials as high or unclear risk of bias (ROB) for sequence generation, potentially introducing bias. However, to date, the extent of this issue has not been well examined. We evaluated the consistency in the ROB assessment for sequence generation of randomised trials in Cochrane and non-Cochrane reviews, and explored the reviewers’ judgement of the quality of evidence for the related outcomes. METHODS: Cochrane intervention reviews (01/01/2017–31/03/2017) were retrieved from the Cochrane Database of Systematic Reviews. We also searched for systematic reviews in ten general medical journals with highest impact factors (01/01/2016–31/03/2017). We examined the proportion of reviews that rated the sequence generation domain as high, low or unclear risk of selection bias. For reviews that had rated any randomised trials as high or unclear risk of bias, we examined the proportion that had assessed the quality of evidence. RESULTS: Overall, 100 systematic reviews were included in our analysis. We evaluated 64 Cochrane reviews which comprised of 984 randomised trials; 0.8% (n = 8) and 52.2% (n = 514) were rated as high and unclear ROB for sequence generation respectively. We further evaluated 36 non-Cochrane reviews which comprised of 1376 trials; 5.8% (n = 80) and 39.6% (n = 545) were rated as high and unclear ROB respectively. Ninety percent (n = 10) of non-Cochrane reviews which rated randomised trials as high ROB for sequence generation did not report an underlying reason. All Cochrane reviews assessed the quality of evidence (GRADE). For the non-Cochrane reviews, only just over half had assessed the quality of evidence. CONCLUSION: Systematic reviews of interventions frequently rate randomised trials as high or unclear ROB for sequence generation. In general, Cochrane reviews were more transparent than non-Cochrane reviews in ROB and quality of evidence assessment. The scientific community should more strongly promote consistent ROB assessment for sequence generation to minimise selection bias and support transparent quality of evidence assessment. Consistency ensures that appropriate conclusions are drawn from the data. |
format | Online Article Text |
id | pubmed-6323681 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-63236812019-01-10 Risk of bias assessment of sequence generation: a study of 100 systematic reviews of trials Wuytack, Francesca Regan, Maria Biesty, Linda Meskell, Pauline Lutomski, Jennifer E. O’Donnell, Martin Treweek, Shaun Devane, Declan Syst Rev Research BACKGROUND: Systematic reviews of randomised trials guide policy and healthcare decisions. Yet, we observed that some reviews judge randomised trials as high or unclear risk of bias (ROB) for sequence generation, potentially introducing bias. However, to date, the extent of this issue has not been well examined. We evaluated the consistency in the ROB assessment for sequence generation of randomised trials in Cochrane and non-Cochrane reviews, and explored the reviewers’ judgement of the quality of evidence for the related outcomes. METHODS: Cochrane intervention reviews (01/01/2017–31/03/2017) were retrieved from the Cochrane Database of Systematic Reviews. We also searched for systematic reviews in ten general medical journals with highest impact factors (01/01/2016–31/03/2017). We examined the proportion of reviews that rated the sequence generation domain as high, low or unclear risk of selection bias. For reviews that had rated any randomised trials as high or unclear risk of bias, we examined the proportion that had assessed the quality of evidence. RESULTS: Overall, 100 systematic reviews were included in our analysis. We evaluated 64 Cochrane reviews which comprised of 984 randomised trials; 0.8% (n = 8) and 52.2% (n = 514) were rated as high and unclear ROB for sequence generation respectively. We further evaluated 36 non-Cochrane reviews which comprised of 1376 trials; 5.8% (n = 80) and 39.6% (n = 545) were rated as high and unclear ROB respectively. Ninety percent (n = 10) of non-Cochrane reviews which rated randomised trials as high ROB for sequence generation did not report an underlying reason. All Cochrane reviews assessed the quality of evidence (GRADE). For the non-Cochrane reviews, only just over half had assessed the quality of evidence. CONCLUSION: Systematic reviews of interventions frequently rate randomised trials as high or unclear ROB for sequence generation. In general, Cochrane reviews were more transparent than non-Cochrane reviews in ROB and quality of evidence assessment. The scientific community should more strongly promote consistent ROB assessment for sequence generation to minimise selection bias and support transparent quality of evidence assessment. Consistency ensures that appropriate conclusions are drawn from the data. BioMed Central 2019-01-08 /pmc/articles/PMC6323681/ /pubmed/30621793 http://dx.doi.org/10.1186/s13643-018-0924-1 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Wuytack, Francesca Regan, Maria Biesty, Linda Meskell, Pauline Lutomski, Jennifer E. O’Donnell, Martin Treweek, Shaun Devane, Declan Risk of bias assessment of sequence generation: a study of 100 systematic reviews of trials |
title | Risk of bias assessment of sequence generation: a study of 100 systematic reviews of trials |
title_full | Risk of bias assessment of sequence generation: a study of 100 systematic reviews of trials |
title_fullStr | Risk of bias assessment of sequence generation: a study of 100 systematic reviews of trials |
title_full_unstemmed | Risk of bias assessment of sequence generation: a study of 100 systematic reviews of trials |
title_short | Risk of bias assessment of sequence generation: a study of 100 systematic reviews of trials |
title_sort | risk of bias assessment of sequence generation: a study of 100 systematic reviews of trials |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323681/ https://www.ncbi.nlm.nih.gov/pubmed/30621793 http://dx.doi.org/10.1186/s13643-018-0924-1 |
work_keys_str_mv | AT wuytackfrancesca riskofbiasassessmentofsequencegenerationastudyof100systematicreviewsoftrials AT reganmaria riskofbiasassessmentofsequencegenerationastudyof100systematicreviewsoftrials AT biestylinda riskofbiasassessmentofsequencegenerationastudyof100systematicreviewsoftrials AT meskellpauline riskofbiasassessmentofsequencegenerationastudyof100systematicreviewsoftrials AT lutomskijennifere riskofbiasassessmentofsequencegenerationastudyof100systematicreviewsoftrials AT odonnellmartin riskofbiasassessmentofsequencegenerationastudyof100systematicreviewsoftrials AT treweekshaun riskofbiasassessmentofsequencegenerationastudyof100systematicreviewsoftrials AT devanedeclan riskofbiasassessmentofsequencegenerationastudyof100systematicreviewsoftrials |